News
-
.2010
Vacc-4x shows statictically significant reduction in viral load
Further analysis of Vacc-4x phase IIb study shows a statistically significant reduction in viral load over placebo – Bionor Pharma reverses decision to put Vacc-4x on hold
-
.2010
Bionor Pharma fails to show a positive effect of its cell-mediated therapeutic HIV-vaccine candidate, Vacc-4x
-
.2010
Two-Thirds Respond to "Re-vaccination "
Two-Thirds of Study Volunteers Respond to First-Ever "Re-vaccination " of Vacc-4x, Bionor Pharma's Peptide-based Therapeutic HIV-Vaccine
-
.2010
Independent research report on Bionor published in Thomson Reuters' "Current Opinion in Investigational Drugs"
To view the research report in its entirety, please follow the link.
-
.2010
BIOtechNOW: International AIDS Conference Unveils Four New “Next Generation” Treatments for HIV
New data presented at the 2010 International AIDS Conference showed significant momentum for the emerging fields of therapeutic vaccines, anti-immune hyperactivation, and other immune based therapies for the treatment of HIV/AIDS.
-
.2010
Results of Vacc-4x HIV vaccine announced
Researchers with the Oslo University and Bionor Immuno at the XVIII International AIDS Conference in Vienna, Austria, recently released the results of a re-vaccination study of Norway’s largest hospital using the company's furthest advance HIV vaccine candidate, Vac-4x
-
.2010
Reuters: Many forks loom in road to AIDS vaccine
(Reuters) - AIDS experts and advocates gathering in Vienna this weekend for a conference on the pandemic will hear about progress in protecting people from the deadly virus using drugs, and ways to affect behavio
-
.2010
Financial Times: HIV / Aids: Discordant visions.
Changing outlook: demonstrators in Cape Town last year raise fears about finance for action to combat the virus. But in contrast to past wariness, South Africa sent its vice-president and minister of health to tell this week’s Vienna conference of a redoubled prevention, testing and treatment effort. The country has one of the highest HIV burdens
-
.2010
Bionor presents at the XVIII International AIDS Conference
Bionor Immuno's Therapeutic HIV Vaccine Candidate Vacc-4x Targeting Conserved Domains of HIV Produce Immune Response Seven Years after Inoculation
-
.2010
Bionor Immuno Researchers Discover Pathway that Allows HIV “Natural Viral Suppressors” to Live Without Symptoms; Study Findings Confirm Potential for Vacc-C5
A study performed in collaboration with the University of Maryland School of Medicine’s Institute for Human Virology leads Bionor Immuno researchers to believe they have found a way to replicate the immune responses previously associated with “natural viral suppressors,” those people who are able naturally to control HIV without medication, the Company announced today
-
.2010
Bionor Pharma's re-vaccination study accepted as a poster at the XVIII International AIDS conference
Bionor Pharma's subsidiary, Bionor Immuno AS recently carried out are-vaccination study at Norway's largest hospital, using Vacc-4x, the company'smost advanced HIV-vaccine candidate
-
.2010
Researchers Find that Investigational Therapeutic HIV Vaccine, Vacc-4x, is still effective (Produces Immune Response) in HIV Study Volunteers Seven Years After Injection
31.05.2010 - Bionor Pharma’s subsidiary, Bionor Immuno AS completed a re-vaccination study at Norway’s largest hospital with Vacc-4x, the company’s most advanced HIV-vaccine candidate
-
.2010
New path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers
16.03.2010 - Vacc-C5 to Move from Lab to Phase I/II Clinical Trial. Based on encouraging results from pre-clinical research, Bionor Immuno AS, today announced intentions to take the therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 into a Phase I/II clinical trial
-
.2010
Vacc-C5 to be prepared for phase I/II clinical tria
15.03.2010 - Based on encouraging results from pre-clinical research, Nutri Pharma ASA's wholly owned subsidiary Bionor Immuno AS, has today announced that it will takethe therapeutic and potentially preventative HIV-vaccine candidate Vacc-C5 towards phase I/II clinical trial